The Tissue Core (the Core) provides both tissue collection and analytic services, and sets the standards for the use of human tissue across all research programs at the UCSF Helen Diller Family Comprehensive Cancer Center (Center), including those that have separately managed tissue-collection efforts. In this latter function. Tissue Core provides oversight and guidance for common issues including tissue consent, standard operating procedures, databases, and quality control (QC). The Core provides tissue-banking services, partially supported by recharge to user programs, including procurement, annotation, processing, storage, tracking, and distribution. Several programs provide direct financial support for Core staff for this purpose. The Core acts as the central hub for the collection of fresh surgical tissue from the hospitals at the Mt. Zion and Moffitt-Long (Parnassus) campuses for those programs without their own tissue- collection efforts. The Core supports the processing, storage, and distribution of blood from patients at UCSF and other sites. In addition, the Core collects, and manages solid tissue from patients at hospitals offsite for several clinical efforts. The Core offers routine histology services, including sectioning, staining, histologic interpretation, and tissue microarray preparation. Distribution of banked material requires approval by the Institutional Review Board (IRB), and by the appropriate programmatic Tissue Utilization Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388374
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$381,002
Indirect Cost
$137,680
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications